NKGen Biotech (NYSE:NKGN) Stock Price Up 5.4%

Shares of NKGen Biotech, Inc. (NYSE:NKGNGet Free Report) rose 5.4% during trading on Friday . The company traded as high as $2.05 and last traded at $1.96. Approximately 536,397 shares changed hands during mid-day trading, a decline of 81% from the average daily volume of 2,790,220 shares. The stock had previously closed at $1.86.

NKGen Biotech Stock Performance

The stock’s fifty day moving average price is $1.83.

Institutional Trading of NKGen Biotech

An institutional investor recently bought a new position in NKGen Biotech stock. University of Chicago purchased a new position in shares of NKGen Biotech, Inc. (NYSE:NKGNFree Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 550,000 shares of the company’s stock, valued at approximately $1,512,000. NKGen Biotech comprises about 2.1% of University of Chicago’s holdings, making the stock its 5th largest holding. University of Chicago owned approximately 2.51% of NKGen Biotech as of its most recent filing with the Securities and Exchange Commission. 28.50% of the stock is currently owned by institutional investors and hedge funds.

NKGen Biotech Company Profile

(Get Free Report)

NKGen Biotech, Inc operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials.

Recommended Stories

Receive News & Ratings for NKGen Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NKGen Biotech and related companies with MarketBeat.com's FREE daily email newsletter.